SkinBioTherapeutics PLC Director/PDMR Shareholding (4957S)

TIDMSBTX

RNS Number : 4957S

SkinBioTherapeutics PLC

09 March 2023

9 March 2023

SkinBioTherapeutics plc

("SBTX" or the "Company")

Director Bed & ISA Dealings

SkinBioTherapeutics plc (AIM: SBTX), the life science company focused on skin health , announces that it received notification on 9 March 2023 that Stuart Ashman , CEO and PDMR , sold 89,472 ordinary shares of 1p each in the Company ("Ordinary Shares") and repurchased 86,387 Ordinary Shares into Mr Ashman's ISA account. Following this transaction Stuart Ashman's beneficial interest in the Company shares has decreased from 281,250 to 278,165 ordinary shares, with the variance owing to commissions and costs of the transactions .

Details of PDMR transaction

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                  Stuart Ashman 
      ------------------------------------  ------------------------------------------------- 
       Reason for the notification 
  2 
      --------------------------------------------------------------------------------------- 
 a)    Position/status                       PDMR (CEO) 
      ------------------------------------  ------------------------------------------------- 
 b)    Initial notification                  Initial notification 
        /Amendment 
      ------------------------------------  ------------------------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------------------- 
 a)    Name                                  SkinBioTherapeutics plc 
      ------------------------------------  ------------------------------------------------- 
 b)    LEI                                   213800YMQOCB23FX6I06 
      ------------------------------------  ------------------------------------------------- 
       Details of the transaction(s): section to be repeated for (i) 
  4     each type of instrument; (ii) each type of transaction; (iii) each 
        date; and (iv) each place where transactions have been conducted 
      --------------------------------------------------------------------------------------- 
 a)    Description of the financial          Ordinary Shares in SkinBioTherapeutics plc 
        instrument, type of 
        instrument 
 
       Identification code                   GB00BF33H870 
 
 b)    Nature of the transaction             Sale and purchase of ordinary shares 
      ------------------------------------  ------------------------------------------------- 
 c)    Price(s) and volume(s) 
                                             ------------------------------  -------------- 
                                              Price(s)                        Volume(s) 
                                             ------------------------------  -------------- 
    Sale at 22.75 p                                                           89,472 
   ------------------------------------------------------------------------  -------------- 
    Purchase at 22.75 
     p                                                                        86,387 
   ------------------------------------------------------------------------  -------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                   n/a 
 
  - Price 
 
 e)    Date of the transactions              6 March 2023 
      ------------------------------------  ------------------------------------------------- 
 f)    Place of the transaction              N/A 
      ------------------------------------  ------------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHQKLFBXXLEBBX

(END) Dow Jones Newswires

March 09, 2023 12:18 ET (17:18 GMT)